

Prevalence of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency among Malaria Patients in Southern Thailand: 8 Years Retrospective Study

Thunchanok Khammanee¹, Nongyao Sawangjaroen¹, Hansuk Buncherd², Aung Win Tun³,
Supinya Thanapongpichat^{2,*} 

¹Division of Biological Science, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand; ²Faculty of Medical Technology, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand; ³Faculty of Graduate Studies, Mahidol University, Salaya, Nakhon Pathom 73170, Thailand

Abstract: Erythrocytes deficient in glucose-6-phosphate dehydrogenase (G6PD) is more susceptible to oxidative damage from free radical derived compounds. The hemolysis triggered by oxidative agents such as primaquine (PQ) is used for the radical treatment of hypnozoites of *P. vivax*. Testing of G6PD screening before malaria treatment is not a common practice in Thailand, which poses patients at risk of hemolysis. This retrospective study aimed to investigate the prevalence of G6PD in malaria patients who live in Southern Thailand. Eight hundred eighty-one malaria patients were collected for 8-year from 2012 to 2019, including 785 (89.1%) of *P. vivax*, 61 (6.9%) of *P. falciparum*, 27 (3.1%) of *P. knowlesi*, and 8 (0.9%) of mixed infections. The DiaPlexC genotyping kit (Asian type) and PCR-RFLP were employed to determine the G6PD variants. The result showed that 5 different types of G6PD variants were identified in 26 cases (2.9%); 12/26 (46.2%) had Mahidol (487G>A) and 11/26 (42.3%) had Viangchan (871G>A) variants, while the rest had Kaiping (1388G>A), Union (1360C>T), and Mediterranean (563C>T) variants. G6PD Songklanagarind (196T>A) variant was not found in the study. Our result did not show a significant difference in the malaria parasite densities in patients between G6PD-deficient and G6PD-normal groups. According to our findings, testing G6PD deficiency and monitoring the potential PQ toxicity in patients who receive PQ are highly recommended.

Key words: G6PD, malaria, *P. vivax*, Southern Thailand

INTRODUCTION

G6PD deficiency is the most common X-linked recessive hereditary enzymopathy in humans, which affects over 500 million people globally [1]. G6PD plays a crucial role in the first step of the pentose phosphate pathway (PPP), which is the only source of generating the co-enzyme, nicotinamide adenine dinucleotide phosphate (NADPH), in RBCs. The NADPH passes the electron to oxidized glutathione (GSSG) in the antioxidant pathway, producing the reduced glutathione (GSH). The GSH generation helps to protect cells from oxidative stress by removing the reactive oxygen species (ROS) [2]. G6PD activity is therefore crucial for protecting cells against oxidative

damage. The gene encoding G6PD is highly polymorphic. Its mutations frequently cause clinical manifestation because of decreased enzyme activity and stability [3]. Most G6PD deficiency patients show no symptoms until exposure to external triggers that could lead to moderate and severe symptoms, such as acute or chronic hemolytic anemia, favism, neonatal jaundice, and hyperbilirubinemia [4]. The hereditary G6PD enzyme deficiency distributes in males and varies among ethnic groups in different geographic regions, ranging from 0% in the native American to 20% or more in African and Asian [1,5]. Notably, the distribution of G6PD deficiency correlates with the malaria-endemic areas [6], showing the evolutionary selection of G6PD deficiency by malaria. The impairment of G6PD conferred the inhibition of *in vitro* parasite growth [7] and the protection against complicated malaria because of the early phagocytosis of infected RBC [8].

Previous clinical studies showed that G6PD A-variant in Africa protects against severe falciparum malaria disease only in hemizygous males [9] or heterozygous female children [10].

•Received 27 August 2021, revised 5 December 2021, accepted 22 December 2021.

*Corresponding author (supinya.th@psu.ac.th)

© 2022, Korean Society for Parasitology and Tropical Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Although G6PD deficiency provides an advantage under natural selection by malaria, the patient with G6PD deficiency who received an anti-malarial drug, e.g., primaquine (PQ), may suffer hemolytic anemia [11]. The PQ prevents the relapse of *P. vivax* and *P. ovale* by killing the hypnozoite in liver cells and blocking the gametocyte of *P. falciparum* [12,13]. The severity of hemolysis depends on G6PD variants. Although the G6PD deficiency is rare, its prevalence in the regions where malaria is common would be over 10% [14]. Howes RE et al. [6] reported approximately 13-17% of Thai population carries common G6PD variants. This global prevalence of G6PD deficiency was estimated using a Bayesian geostatistical model which predicted the allele frequency of the G6PD deficiency map across endemic malaria countries. Among the Thai population, G6PD Mahidol, Viangchan, Canton, Kaiping, Mediterranean, Songklanagarind, Union, Vanua Lava, Chinese-5, Gaohe, Kerala-Kalyan and Quing Yan were observed. The G6PD variants are diverse among ethnicities and geographical regions. The Mahidol and Viangchan variants were the most common among Thais and people of other races. In the Thai population, G6PD Mahidol was as high as 94.92% of Thais living near the Thai-Myanmar border [15] while it was 20% in the north [16]. In contrast, Viangchan variant was dominant in southern Thailand with 46.8% found in Surat Thani province [17], 24.14% in Phuket province [18], and 31.3% in Songkhla province [19]. Among ethnic groups, G6PD Mahidol variant was detected in more than 90% of Karen and Myanmar people in the north-west [20], and 13.1% of Myanmar [17], and 37.9% of Moken people in the south [18]. In the Northeast, 31% of the Lo ethnic group carried the G6PD Viangchan variation [21]. In addition, Chinese G6PD mutations were found significant numbers in the northern region. Kaiping G6PD variant was found in 5.4% and 18%, and the Canton variant was 6.42% and 16% were presented in the Lue and Thai ethnic groups, respectively [16, 22].

However, G6PD deficiency testing in malaria patient is required before PQ administration, but the procedure is poorly implemented [11]. Information about the distribution of the G6PD variants would be necessary for the implication of primaquine policy. Even though several studies have reported the prevalence of G6PD deficiency in malaria patients from elsewhere in Thailand [23,24]. There is a limited data available for the southern Thailand, where malaria is still a problem and potential to increase. There has been no assessment of the G6PD deficiency frequencies in malaria-infected patients who

resided or worked in malaria-endemic areas of southern Thailand. Therefore, the present study aims to investigate the prevalence of G6PD variants in malaria patients from southern Thailand.

MATERIALS AND METHODS

Ethical statement

This study was approved by the Ethical Review Committee for Research in Human Subjects, Prince of Songkla University (HSc-HREC-63-6-1-1).

Study area and subjects

This retrospective study was performed using dried blood spots samples from the previous study conducted in the southern Thailand [25-27], during 2012-2019. A total of 881 dried blood spots samples were diagnosed with malaria infection by the microscopic method from the malaria clinics at the Office of Disease Prevention and Control 11 and 12, Thailand. All finger-prick dried blood spot samples were collected on Whatman No.3 filter paper (GE Healthcare, Buckinghamshire, UK). These samples had been registered at malaria clinics from 5 sites in the Southern regions of Thailand: Ranong, Chumphon, Phang-nga, Surat Thani (located in the upper part of the south), and Yala (the southernmost province).

At the malaria clinic, microscopic examination of thick and thin smears was performed to detect infection, to estimate parasitemia and identify the parasite stage. The malaria parasites were counted against 200 white blood cells of thick film and 1,000 red blood cells of the thin film. Then, the parasite density (parasites/ μ l) was calculated from the number of parasites counted per 200 WBCs \times 8,000 cells/ μ l (assumed WBC count in patients) of thick film and parasitized cells \times an estimated 5,000,000 average red cells divided by 20 fields \times 250 RBCs for thin blood smear [28]. The parasitic density was a geometric mean of 4,236 parasites/ μ l (95% CI, 8-47,607 parasites/ μ l (assuming WBCs (8,000/ μ l of blood). *P. vivax* infected individuals were treated with 25 mg/kg chloroquine and 0.25 mg/kg primaquine for 14 days as the first-line drugs according to the Ministry of Public Health, Thailand.

Plasmodium detection and G6PD variants analysis

Genomic DNA was extracted using QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendation for dried blood spots. DNA was

eluted in 100 µl of the elution buffer and used as templates for molecular approach. *Plasmodium* parasites species *P. falciparum*, *P. vivax*, *P. ovale*, and *P. malariae* were confirmed by nested PCR assay based on the 18S ribosomal RNA (18S rRNA) gene as described previously [29]. *P. knowlesi* species was confirmed with the cytochrome *b* (*Cyt b*) gene by nested PCR assay [30]. G6PD genotyping variants were identified using DiaPlexC™ G6PD Genotyping Kit (Asian type; SolGent, Korea) with one-step PCR. The different amplicon sizes from the 8 G6PD variants were produced as follow: Vanua Lava (383T>C, 154 bp), Mediterranean (563C>T, 262 bp), Coimbra (592C>T, 234 bp), Mahidol (4,87G>A, 337 bp), Viangchan (871 G>A, 501 bp), Kaiping (1,388G>A, 557 bp), Canton (1,376G>T, 681 bp) and Union (1,360C>T, 803 bp). Amplification was performed with an initial denaturation at 95°C for 15 min; 30 cycles of 95°C for 30 sec, 60°C for 30 sec, and 72°C for 40 sec; and a final extension at 72°C for 5 min. PCR reactions were conducted in a 25 µl reaction mixture containing 5 µl of template, 12.5 µl of 2X multiplex PCR smart mix (G6PD Asian type), 2 µl of primer mixer (G6PD Asian type), 5.5 µl of nuclease-free water. The PCR products were resolved on 3% agarose gels electrophoresis at 100 V in the Tris-Borate-EDTA buffer and then visualized by UV light after staining with ethidium bromide. The internal control was confirmed at band 1,234 bp. G6PD Songklanagarind, the nucleotide changed from the TTC>ATC at codon 196 in the exon 4 of the G6PD gene, was detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). A pair of primers and PCR conditions were used as previously described [19]. According to the manufacturer's instruction, the PCR products were digested with 10 U of FastDigest BstXI (Thermo Fisher Scientific, Waltham, Massachusetts, USA).

Data analysis

Malaria parasite density was determined in the G6PD deficient and non-deficient groups using the student's t-test. The parasite count on a thick film was examined, consisting of 686/785 of *P. vivax* and 48/57 of *P. falciparum* and 8 samples were mixed infections between *P. vivax* and *P. falciparum*.

RESULTS

Prevalence of G6PD mutation variants

The study was conducted in Ranong ($n=178$), Chumphon ($n=75$), Phang-nga ($n=7$), Surat Thani ($n=59$) and Yala ($n=$

562). Among 881 malaria patients, 298 (33.9%) were females, and 506 (57.4%) were males, while no data was available for the rest 77 (8.7%). The majority of the patients were Thai (779; 88.4%), followed by Myanmar (99; 11.3%) and Laos (3; 0.4%), respectively (Fig. 1 and Table 1). *P. vivax* was detected in 785 (89.1%), *P. falciparum* in 61 (6.9%), *P. knowlesi* in 21 (3.1%), and mixed infection in 8 (0.9%) (*P. vivax* and *P. falciparum*) of the patients. The G6PD variants were detected in 26 out of 881 patients (2.9%) and the rest 855 patients were normal G6PD individuals (97.1%). The prevalence of 26 G6PD-deficient persons varied by the locations represented in Table 1. In order of prevalence from highest to lowest, they were 28.6% (2/7) in Phang-nga, 7.4% (13/178) in Ranong, 5.4% (4/75) in Phumphon, 1.8% (1/59) in Surat Thani and 1.1% (6/562) from 1.1% (6/562) in Yala. These 26 samples had 5 different G6PD variants: Mahidol variant comprised 46.2% (12/26); Viangchan variant 42.3% (11/26), and a single case each of Kaiping, Union, and Mediterranean (3.85% of each). There was no Songklanagarind variant observed in this study. Among the G6PD deficiency individuals, 73.1% (19/26) were Thais, 23.1% (6/26) Burmese and 3.8% (1/26) Laos, while 13/26 (50%) were males and 8/26 (38.5%) females (Table 1). Only the samples infected with *P. falciparum* and *P. vivax* had G6PD variants, while *P. knowlesi*-infected blood samples possessed normal G6PD. As illustrated in Fig. 1, the prevalence and type of G6PD-deficiency varied among the regions: from 1.1% (6/562) in Yala to 7.3% (13/178) in Ranong. Ranong province at the Thai-Myanmar border showed a high frequency of the persons carrying G6PD variants, both in Thai and Burmese individuals with 53.8% (7/13) and 46.1% (6/13) respectively (Table 1). Among the Burmese ethnic group, 66.6% (4/6) of G6PD Mahidol and 33.4% (2/6) of G6PD Kaiping and Union, were observed respectively. G6PD mutations with a rate of 5.3% (4/75) were identified as Mahidol and Viangchan variants from Chumphon. Of these, 25% (1/4) was Mahidol variant observed in Lao, and the rest 75% (3/4) were Thais with 66.7% (2/3) of Mahidol and 33.3% (1/3) of Viangchan variants, respectively. One Thai patient with Mahidol variant, accounting for 1.7% (1/59), was found in Surat Thani. G871A mutation of G6PD Viangchan was observed in 2 out of 7 (28.6%) Thai patients from Phang-nga. In Yala province, 6 out of 562 samples (1.1%) were found to contain G6PD mutations, of which 66.7% (4/6) and 33.3% (2/6) were Mahidol and Viangchan variants, respectively. As described above, G6PD deficiency was relatively higher in the upper south provinces than




Fig. 1. Geographic distribution of G6PD deficiency variants among malaria-infected individuals in the 5 provinces of southern Thailand.

Table 1. Frequency of G6PD deficiency in southern Thailand

	Normal (%)	G6PD variants (%)	Total (%)
<i>Plasmodium</i> parasites			
<i>P. vivax</i>	764 (97.3)	21 (2.7)	785 (89.1)
<i>P. falciparum</i>	57 (93.4)	4 (6.5)	61 (6.9)
<i>P. knowlesi</i>	27 (100)	0	27 (3.1)
Mixed <i>P. vivax</i> and <i>P. falciparum</i>	7 (87.5)	1 (12.5)	8 (0.9)
Mutations			
Mahidol (487G>A)	-	12 (46.2)	12 (1.4)
Viangchan (871G>A)	-	11 (42.4)	11 (1.3)
Kaiping (1388G>A)	-	1 (3.8)	1 (0.1)
Union (1360C>T)	-	1 (3.8)	1 (0.1)
Mediterranean (563C>T)	-	1 (3.8)	1 (0.1)
Gender			
Male	492 (97.2)	14 (2.8)	506 (57.4)
Female	287 (96)	12 (4)	298 (33.9)
No data	77 (100)	-	77 (8.7)
Ethnics			
Thai	760 (97.6)	19 (2.4)	779 (88.4)
Burmese	93 (93.9)	6 (6.1)	99 (11.2)
Laos	2 (66.7)	1 (33.3)	3 (0.4)
Locations			
Ranong	165 (92.6)	13 (7.4)	178 (20.2)
Chumphon	71 (94.7)	4 (5.3)	75 (8.5)
Phang-nga	5 (71.4)	2 (28.6)	7 (0.8)
Surat Thani	58 (98.2)	1 (1.8)	59 (6.7)
Yala	556 (98.9)	6 (1.1)	562 (63.8)
Total number	855 (97.1)	26 (2.9)	881 (100)




Fig. 2. Comparison of parasitemia between patients with G6PD deficiency and normal.

in the lower part. Mahidol and Viangchan variants were the highest distribution in the upper south regions.

Associations between G6PD deficiency and parasitemia

Parasite densities were compared among the G6PD-deficient ($n=24$) and G6PD-normal ($n=718$) samples. The average of parasite densities of G6PD-deficient and G6PD-normal samples were 4,456 (80-28,118 parasites/ μl) and 4,141 (8-47,607 parasites/ μl), respectively. There was no significant difference in parasitemia between G6PD-deficient and G6PD-normal groups (two-tailed unpaired *t*-test, $P=0.539$; Fig. 2). Fig. 3 describes the relationship between parasitemia and each of the variants of G6PD deficiency. The patients bearing the commonest variants, Viangchan and Mahidol, presented 2,738 parasites/ μl (80-6,823 parasites/ μl) and 6,098 parasites/ μl (538-28,118 parasites/ μl) in the blood. The parasitemia of the 3 individuals with Kaiping, Union, and Mediterranean variants was 3,701, 107, and 11,551 parasites/ μl , respectively. In addition, the data showed that the mean of parasitemia of G6PD-deficient individuals infected with *P. vivax* was higher than that of *P. falciparum* infection, 4,717 parasites/ μl (538-28,118 parasites/ μl ; $n=19$) versus 3,832 parasites/ μl (80-11,551 parasites/ μl ; $n=4$), respectively.

DISCUSSION

The present retrospective cohort study investigates the prevalence of G6PD variants in malaria patients isolated from southern Thailand. The performance of G6PD screening before malaria treatment is uncommon in Thailand, which could impose




Fig. 3. Analysis of parasitemia among patients carrying the different G6PD variants.

the patients at risk of hemolysis. G6PD deficient populations were relatively more common in the upper provinces of southern Thailand than in the southernmost region. In Yala province where there were a higher number of malaria cases, the prevalence of the G6PD variant was relatively lower. According to Howes RE et al. [6], approximately 13-17% of the Thai population carries common G6PD variants. In this study, we analyzed the G6PD genotyping in only the southern region of Thailand. Twenty-six out of 881 malaria samples (2.9%) were identified as the G6PD mutation variants. The previous study, however, did not find G6PD variants in samples isolated from the southern region due to limited of the samples size, whereas the western, central and north-eastern regions presented G6PD variants in 5.36%, 14.28%, and 4.76% respectively [15]. Another study in the southern region revealed that 15.4% and 15.5% of healthy Phuket locals of Moken and Thai carried G6PD variants [23]. The lower prevalence of G6PD mutation variants observed in the present study might be due to the limitation of the DiaPlexC G6PD Genotyping Kit (Asian type) which is unable to detect the certain variants such as G6PD Quing Yuan, silent mutation, G6PD Gaohe [19], G6PD Namoru, G6PD Chatham and, G6PD Andalus [31,32].

World Health Organization has classified G6PD variants, based on the level of enzyme activity, into 5 classes from the most severe (Class I) to the mildest (Class IV): Class I, severe deficiency of the enzyme with chronic non-spherocytic hemolytic anemia; Class II severe deficiency with enzyme activity < 10% of normal; Class III, moderate deficiency with enzyme

activity 10-60% of normal; Class IV, very mild to none deficiency with enzyme activity 60-100% of normal; and Class V, increased enzyme activity [33]. Five types of G6PD mutation variants were identified in this study; Mahidol, Viangchan variants are associated with Class III variants, whereas Kaiping, Union, Mediterranean are associated with Class II variants [34]. However, clinical manifestations are an association between the phenotype and the genotype [35-38]. The low level of G6PD enzyme activity that is presented in G6PD mutations are risk of individuals hematologic changes such as hematocrit drops [39-41].

The Mahidol variant (487G>A) and G6PD Viangchan (871G>A) were the most predominant variants in our study. The previous studies also identified G6PD Mahidol and Viangchan variants as the major variants among healthy individuals in southern Thailand [17,18]. These variants were also commonly present in neighboring countries, including Cambodia, Laos, Myanmar [23,42]. We detected a small portion of G6PD Kaiping (1,388G>A), Union (1,360C>T), and Mediterranean (563C>T). Kaiping and Union variants were detected in the Burmese population. Kaiping variants were the most prevalent among the Chinese population in Southern China [43] and Malaysia [44]. It was also found at high frequency among Thai people of southern Thailand [30]. G6PD Mediterranean was commonly predominant in west Asia [5].

Our present study also showed that there was no difference in parasitemia between the G6PD-deficient and G6PD-normal patients. This was in agreement with the previous reports [20,45], which also suggested the absence of significant association between G6PD deficiency and parasite densities. *P. vivax* is preferentially infecting young red blood cells or reticulocytes, and hence, malaria parasites can replicate within these cells with the normal G6PD enzyme level [46]. A recent study has revealed that parasites produced their own G6PD enzyme to survive within the host red cell [47]. The other report suggests that the parasitized G6PD-deficient erythrocytes were susceptible to phagocytosis by monocytes, which could protect against malaria [48]. Although malaria cases in Thailand have significantly declined, the southern part of Thailand is still facing a high risk of malaria. The region shares 2 borders, with Malaysia in the south and Myanmar in the west, and the greater risk was related to high population mobility along the Myanmar-Thai border and social unrest in provinces bordering with Malaysia [13]. In recent years, *P. vivax* malaria cases have increased from 72% in 2016 to 83% in 2019, even though

P. falciparum showed a reduction in patients [49]. *P. vivax* parasites are the main species causing severe illness and are relapsing. PQ with the daily dose of 0.25 mg/kg in 14-day regimen is prescribed to eliminate the dormant hypnozoites [11]. Prescribing PQ without G6PD testing has been reported to cause hemolysis in *P. vivax* infected patients, particularly at risk for the individuals with low G6PD enzyme activity. Even with the correct dose, intravascular hemolysis in male with G6PD Mahidol variant can occur [50]. It has been demonstrated that the G6PD Viangchan and Mahidol, the most common variants observed in southern Thailand, cause low enzymatic activity in RBCs and risk for acute hemolysis induced by PQ [51,52].

In this study, all dried blood samples were collected from malaria patients attending the malaria clinics. Before giving with Primaquine, the testing for G6PD deficiency is not available according to the national policy for malaria treatment. Hence, the measurement of G6PD enzyme activities is not generally considered at that time. In addition, the methods to determine the G6PD enzyme activity, such as spectrophotometry assay, cytochemical staining assay, fluorescent spot test, and point-of-care G6PD testing, are complex to perform in a field study. Hence, the lack of quantitative measurement of G6PD enzyme activity is a limitation of this study. However, the close relationship between G6PD variants and G6PD phenotypes has been established [35-38]. Further study is required to investigate the level of the G6PD enzyme activity associated with malaria-infected subjects. Therefore, our study highlights the importance of G6PD testing before PQ treatment to prevent hemolysis, raising awareness among healthcare policy-makers and supporting the Thailand malaria elimination program.

ACKNOWLEDGMENT

Funding for this study was provided by a grant from Prince of Songkla University, contract no. MET6302044S and PSU-Ph.D. Scholarship contract no. PSU_PHD2562-004.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

REFERENCES

1. Luzzatto L, Nannelli C, Notaro R. Glucose-6-phosphate dehy-

- drogenase deficiency. *Hematol Oncol Clin North Am* 2016; 30: 373-393. <https://doi.org/10.1016/j.hoc.2015.11.006>
2. Gómez-Manzo S, Marcial-Quino J, Ortega-Cuellar D, Serrano-Posada H, González-Valdez A, Vanoye-Carlo A, Hernández-Ochoa B, Sierra-Palacios E, Castillo-Villanueva A, Reyes-Vivas H. Functional and biochemical analysis of glucose-6-phosphate dehydrogenase (G6PD) variants: elucidating the molecular basis of G6PD deficiency. *Catalysts* 2017; 7: 135. <https://doi.org/10.3390/catal7050135>
 3. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. *Lancet* 2008; 371: 64-74. [https://doi.org/10.1016/S0140-6736\(08\)60073-2](https://doi.org/10.1016/S0140-6736(08)60073-2)
 4. Frank JE. Diagnosis and management of G6PD deficiency. *Am Fam Physician* 2005; 72: 1277-1282.
 5. Howes RE, Dewi M, Piel FB, Monteiro WM, Battle KE, Messina JP, Sakuntabhai A, Satyagraha AW, Williams TN, Baird JK, Hay SI. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. *Malar J* 2013; 12: 418. <https://doi.org/10.1186/1475-2875-12-418>
 6. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, Hogg MM, Battle KE, Padilla CD, Baird JK, Hay SI. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. *PLoS Med* 2012; 9: e1001339. <https://doi.org/10.1371/journal.pmed.1001339>
 7. Pathak V, Colah R, Ghosh K. Effect of inherited red cell defects on growth of *Plasmodium falciparum*: An in vitro study. *Indian J Med Res* 2018; 147: 102-109. https://doi.org/10.4103/ijmr.IJMR_1146_16
 8. Cappadoro M, Giribaldi G, O'Brien E, Turrini F, Mannu F, Ulliers D, Simula G, Luzzatto L, Arese P. Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by *Plasmodium falciparum* may explain malaria protection in G6PD deficiency. *Blood* 1998; 92: 2527-2534. <https://doi.org/10.1182/blood.V92.7.2527>
 9. Guindo A, Fairhurst RM, Doumbo OK, Wellems TE, Diallo DA. X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. *PLoS Med* 2007; 4: e66. <https://doi.org/10.1371/journal.pmed.0040066>
 10. Uyoga S, Ndila CM, Macharia AW, Nyutu G, Shah S, Peshu N, Clarke GM, Kwiatkowski DP, Rockett KA, Williams TN. Glucose-6-phosphate dehydrogenase deficiency and the risk of malaria and other diseases in children in Kenya: a case-control and a cohort study. *Lancet Haematol* 2015; 2: 437-444. [https://doi.org/10.1016/S2352-3026\(15\)00152-0](https://doi.org/10.1016/S2352-3026(15)00152-0)
 11. Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries. *PLoS Negl Trop Dis* 2018; 12: e0006230. <https://doi.org/10.1371/journal.pntd.0006230>
 12. World Health Organization. Testing for G6PD deficiency for safe use of primaquine in radical cure of *P. vivax* and *P. ovale*: Policy brief. Geneva, Switzerland. World Health Organization. 2016. <https://apps.who.int/iris/handle/10665/250297>
 13. USAID. President's Malaria Initiative: Thailand, Lao PDR and Regional Abbreviated Malaria Operation Plan FY 2019 [Internet]. United States Agency for International Development; [cited 2022 Jan 22]. Available from: <https://d1u4sg1s9ptc4z.cloudfront.net/uploads/2021/03/fy-2019-thailand-abbreviated-malaria-operational-plan.pdf>
 14. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. Global extent of chloroquine-resistant *Plasmodium vivax*: a systematic review and meta-analysis. *Lancet Infect Dis* 2014; 14: 982-991. [https://doi.org/10.1016/S1473-3099\(14\)70855-2](https://doi.org/10.1016/S1473-3099(14)70855-2)
 15. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. *Blood Cells Mol Dis* 2009; 42: 267-278. <https://doi.org/10.1016/j.bcmd.2008.12.005>
 16. Boonyuen U, Songdej D, Tanyaratsrisakul S, Phuanukoonnon S, Chamchoy K, Praoparotai A, Pakparnich P, Sudsumrit S, Edwards T, Williams CT, Byrne RL, Adams ER, Imwong M. Glucose-6-phosphate dehydrogenase mutations in malaria endemic area of Thailand by multiplexed high-resolution melting curve analysis. *Malar J* 2021; 20: 194. <https://doi.org/10.1186/s12936-021-03731-0>
 17. Charoenkwan P, Tantiprabha W, Sirichotiyakul S, Phusua A, Sanguansermsri T. Prevalence and molecular characterization of glucose-6-phosphate dehydrogenase deficiency in northern Thailand. *Southeast Asian J Trop Med Public Health* 2014; 45: 187-193.
 18. Jitueakul S, Buncherd H, Thawornpan P, Tun AW, Thanapongpichat S. Characterization of G6PD genotypes in G6PD deficiency patients from Suratthani Hospital, Thailand. *JAMS* 2018; 51: 66-71.
 19. Ninokata A, Kimura R, Samakkam U, Settheetham-Ishida W, Ishida T. Coexistence of five G6PD variants indicates ethnic complexity of Phuket islanders, Southern Thailand. *J Hum Genet* 2006; 51: 424-428. <https://doi.org/10.1007/s10038-006-0380-y>
 20. Laosombat V, Sattayasevana B, Janejindamai W, Viprakasit V, Shirakawa T, Nishiyama K, Matsuo M. Molecular heterogeneity of glucose-6-phosphate dehydrogenase (G6PD) variants in the south of Thailand and identification of a novel variant (G6PD Songklanagarind). *Blood Cells Mol Dis* 2005; 34: 191-196. <https://doi.org/10.1016/j.bcmd.2004.11.001>
 21. Bancone G, Chu CS, Somsakchaicharoen R, Chowwiwat N, Parker DM, Charunwathana P, White NJ, Nosten FH. Characterization of G6PD genotypes and phenotypes on the northwestern Thailand-Myanmar border. *PLoS One*. 2014; 9: e116063. <https://doi.org/10.1371/journal.pone.0116063>
 22. Kanchanavithayakul A, Prasittisa K, Kiat-Amomrak P, Chanda M, Kittiwatanasarn P, Nuchprayoon I, Cheepsunthorn CL. Prevalence of glucose 6-phosphate dehydrogenase deficiency and genetic mutations among karen and lao populations in thailand. *Southeast Asian J Trop Med Public Health* 2017; 48: 1308-1317.
 23. Sathupak S, Leecharoenkiat K, Kampuansai J. Prevalence and molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Lue ethnic group of northern Thailand. *Sci Rep* 2021; 11: 2956. <https://doi.org/10.1038/s41598-021-82477-w>

24. Phompradit P, Kuesap J, Chaijaroenkul W, Rueangweerayut R, Hongkaew Y, Yamnuan R, Na-Bangchang K. Prevalence and distribution of glucose-6-phosphate dehydrogenase (G6PD) variants in Thai and Burmese populations in malaria endemic areas of Thailand. *Malar J* 2011; 10: 368. <https://doi.org/10.1186/1475-2875-10-368>
25. Bonito B, Polrat Wilairatana P, Tangpukdee N, Muangnoicharoen S, Poovorawan K, Srivicha Krudsood S. Prevalence of glucose-6-phosphate dehydrogenase deficiency among vivax malaria patients at the Hospital for Tropical Diseases, Thailand. *Southeast Asian J Trop Med Public Health* 2019; 50: 211-216.
26. Khammanee T, Sawangjaroen N, Buncherd H, Tun AW, Thanapongpichat S. A LAMP-SNP assay detecting C580Y mutation in *Pfkelch13* gene from clinically dried blood spot samples. *Korean J Parasitol* 2021; 59: 15-22. <https://doi.org/10.3347/kjp.2021.59.1.15>
27. Khammanee T, Sawangjaroen N, Buncherd H, Tun AW, Thanapongpichat S. Molecular surveillance of *Pfkelch13* and *Pfmdr1* mutations in *Plasmodium falciparum* isolates from Southern Thailand. *Korean J Parasitol* 2019; 57: 369-377. <https://doi.org/10.3347/kjp.2019.57.4.369>
28. Thanapongpichat S, Khammanee T, Sawangjaroen N, Buncherd H, Tun AW. Genetic diversity of *Plasmodium vivax* in clinical isolates from Southern Thailand using *PvMSP1*, *PvMSP3* (*PvMSP3alpha*, *PvMSP3beta*) genes and eight microsatellite markers. *Korean J Parasitol* 2019; 57: 469-479. <https://doi.org/10.3347/kjp.2019.57.5.469>
29. Schoone GJ, Oskam L, Kroon NC, Schallig HD, Omar SA. Detection and quantification of *Plasmodium falciparum* in blood samples using quantitative nucleic acid sequence-based amplification. *J Clin Microbiol* 2000; 38: 4072-5407. <https://doi.org/10.1128/JCM.38.11.4072-4075.2000>
30. Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN. Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. *Mol Biochem Parasitol* 1993; 58: 283-292. [https://doi.org/10.1016/0166-6851\(93\)90050-8](https://doi.org/10.1016/0166-6851(93)90050-8)
31. Iwagami M, Nakatsu M, Khattignavong P, Soundala P, Lorphachan L, Keomalaphet S, Xangsyalath P, Kawai S, Hongyathong B, Brey PT, Kano S. First case of human infection with *Plasmodium knowlesi* in Laos. *PLoS Negl Trop Dis* 2018; 12: e0006244. <https://doi.org/10.1371/journal.pntd.0006244>
32. Ainoon O, Yu YH, Amir Muhriz AL, Boo NY, Cheong SK, Hamidah NH. Glucose-6-phosphate dehydrogenase (G6PD) variants in Malaysian Malays. *Hum Mutat* 2003; 21: 101. <https://doi.org/10.1002/humu.9103>
33. Yusoff NM, Shirakawa T, Nishiyama K, Ghazali S, Ee CK, Orita A, Abdullah WZ, Isa MN, Van Rostenberghe H, Matsuo M. Molecular heterogeneity of glucose-6-phosphate dehydrogenase deficiency in Malays in Malaysia. *Int J Hematol* 2002; 76: 149-152. <https://doi.org/10.1007/BF02982577>
34. World Health Organization. Updating the WHO G6PD classification of variants and the International Classification of Diseases, 11th Revision (ICD-11). Malaria Policy Committee Meeting. Background document for Session 7. 2019 October 2-4; Geneva, Switzerland. <https://www.who.int/malaria/mpac/mpac-october2019-session7-updating-G6PD-classification.pdf>
35. Lee J, Kim TI, Kang JM, Jun H, Lê HG, Thái TL, Sohn WM, Myint MK, Lin K, Kim TS, Na BK. Prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency among malaria patients in Upper Myanmar. *BMC Infect Dis* 2018; 18: 131. <https://doi.org/10.1186/s12879-018-3031-y>
36. World Health Organization. Guide to G6PD Deficiency Rapid Diagnostic Testing to Support *P. vivax* Radical Cure. World Health Organization. Geneva, Switzerland. 2018. <https://apps.who.int/iris/bitstream/handle/10665/272971/9789241514286-eng.pdf>
37. Huang Y, Choi MY, Au SW, Au DM, Lam VM, Engel PC. Purification and detailed study of two clinically different human glucose 6-phosphate dehydrogenase variants, G6PD(Plymouth) and G6PD(Mahidol): Evidence for defective protein folding as the basis of disease. *Mol Genet Metab* 2008; 93: 44-53. <https://doi.org/10.1016/j.ymgme.2007.08.122>
38. Gómez-Manzo S, Terrón-Hernández J, De la Mora-De la Mora I, González-Valdez A, Marcial-Quino J, García-Torres I, Vanoye-Carlo A, López-Velázquez G, Hernández-Alcántara G, Oriá-Hernández J, Reyes-Vivas H, Enríquez-Flores S. The stability of G6PD is affected by mutations with different clinical phenotypes. *Int J Mol Sci* 2014; 15: 21179-21201. <https://doi.org/10.3390/ijms151121179>
39. Au SW, Gover S, Lam VM, Adams MJ. Human glucose-6-phosphate dehydrogenase: the crystal structure reveals a structural NADP(+) molecule and provides insights into enzyme deficiency. *Structure* 2000; 8: 293-303. [https://doi.org/10.1016/s0969-2126\(00\)00104-0](https://doi.org/10.1016/s0969-2126(00)00104-0)
40. Kaplan JC. Defective molecular variants of glucose-6-phosphate dehydrogenase and methaemoglobin reductase. *J Clin Pathol Suppl (R Coll Pathol)* 1974; 8: 134-141.
41. Piomelli S, Corash LM, Davenport DD, Miraglia J, Amorosi EL. In vivo lability of glucose-6-phosphate dehydrogenase in GdA- and GdMediterranean deficiency. *J Clin Invest* 1968; 47: 940-948. <https://doi.org/10.1172/JCI105786>
42. Bancone G, Chu CS. G6PD Variants and haemolytic sensitivity to primaquine and other drugs. *Front Pharmacol* 2021; 12: 638885. <https://doi.org/10.3389/fphar.2021.638885>
43. Khim N, Benedet C, Kim S, Kheng S, Siv S, Leang R, Lek S, Muth S, Chea N, Chuor CM, Duong S, Kerleguer A, Tor P, Chim P, Canier L, Witkowski B, Taylor WR, Ménard D. G6PD deficiency in *Plasmodium falciparum* and *Plasmodium vivax* malaria-infected Cambodian patients. *Malar J* 2018; 12: 171. <https://doi.org/10.1186/1475-2875-12-171>
44. Jiang W, Yu G, Liu P, Geng Q, Chen L, Lin Q, Ren X, Ye W, He Y, Guo Y, Duan S, Wen J, Li H, Qi Y, Jiang C, Zheng Y, Liu C, Si E, Zhang Q, Tian Q, Du C. Structure and function of glucose-6-phosphate dehydrogenase-deficient variants in Chinese population. *Hum Genet* 2006; 119: 463-478. <https://doi.org/10.1007/s00439-005-0126-5>

45. Wang J, Luo E, Hirai M, Arai M, Abdul-Manan E, Mohamed-Isa Z, Hidayah N, Matsuoka H. Nine different glucose-6-phosphate dehydrogenase (G6PD) variants in a Malaysian population with Malay, Chinese, Indian and Orang Asli (aboriginal Malaysian) backgrounds. *Acta Med Okayama* 2008; 62: 327-332. <https://doi.org/10.18926/AMO/30966>
46. Lo E, Zhong D, Raya B, Pestana K, Koepfli C, Lee MC, Yewhalaw D, Yan G. Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia. *Malar J* 2019; 18: 340. <https://doi.org/10.1186/s12936-019-2981-x>
47. Kitcharoen S, Dechyotin S, Khemtonglang N, Kleesuk C. Relationship among glucose-6-phosphate dehydrogenase (G-6-PD) activity, G-6-PD variants and reticulocytosis in neonates of northeast Thailand. *Clin Chim Acta* 2015; 442: 125-129. <https://doi.org/10.1016/j.cca.2015.01.017>
48. López C, Saravia C, Gomez A, Hoebeke J, Patarroyo MA. Mechanisms of genetically-based resistance to malaria. *Gene* 2010 467: 1-12. <https://doi.org/10.1016/j.gene.2010.07.008>
49. Ayi K, Turrini F, Piga A, Arese P. Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait. *Blood* 2004; 104: 3364-3371. <https://doi.org/10.1182/blood-2003-11-3820>
50. Udom C, Thanispong K, Manguin S, Chareonviriyaphap T, Fungfuang W. Trophic Behavior and species diversity of the *Anopheles barbirostris* Complex (Diptera: Culicidae) in Thailand. *J Med Entomol* 2021; 58: 2376-2384. <https://doi.org/10.1093/jme/tjab067>
51. Chu CS, Bancone G, Soe NL, Carrara VI, Gornsawun G, Nosten F. The impact of using primaquine without prior G6PD testing: a case series describing the obstacles to the medical management of haemolysis. *Wellcome Open Res* 2019; 4: 25. <https://doi.org/10.12688/wellcomeopenres.15100.2>
52. Rueangweerayut R, Bancone G, Harrell EJ, Beelen AP, Kongpatanakul S, Möhrle JJ, Rousell V, Mohamed K, Qureshi A, Narayan S, Yubon N, Miller A, Nosten FH, Luzzatto L, Duparc S, Kleim JP, Green JA. Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (*G6PD Mahidol* Variant) versus G6PD-normal volunteers. *Am J Trop Med Hyg* 2017; 97: 702-711. <https://doi.org/10.4269/ajtmh.16-0779>
53. Chu CS, Bancone G, Nosten F, White NJ, Luzzatto L. Primaquine-induced haemolysis in females heterozygous for G6PD deficiency. *Malar J* 2018; 17: 101. <https://doi.org/10.1186/s12936-018-2248-y>